Amgen

Open: 227.79 Close: 232.57 Change: 4.78

14 things an AI found about Amgen Company Inc Stock that you should know before investing.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, price, AMGN, earnings, Therapeutics, NASDAQAMGN, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen (AMGN) closed at $227.66, marking a +0.88% move from the previous day. Amgen has its Repatha (evolocumab) PCSK9i inhibitor that lowers LDL-C levels by more than 50 percent. Amgen (AMGN) closed the most recent trading day at $227.66, moving +0.88% from the previous trading session. Amgen has consistently generated strong revenue figures, with a reported revenue of $23.4 billion in 2020.

Today's News

Amgen Inc. (AMGN) stock price, quote & news - stock analysis. amgn | amgen inc. stock overview. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. FTC faces uphill battle in its fight to block Amgens $27.8 billion takeover of Horizon Therapeutics. Amgen has made pursuing drug targets validated by human genetics. Amgen (AMGN) closed at $227.66, marking a +0.88% move from the previous day. Amgen has its Repatha (evolocumab) PCSK9i inhibitor that lowers LDL-C levels by more than 50 percent. Amgen (AMGN) reported Q1 2023 earnings per share (EPS) of $5.28 beating estimates of $3.85 by 37.26%. Amgen is expected to release next earnings on 08/03/2023 with an earnings per estimate of $4.47. The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck. Amgen (AMGN) stock price for Amgen is $ 232.57 last updated at 8:00 UTC. Amgen stock price is $2.13 per share. Shareholders pay a quarterly dividend of $2. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease. Amgen (NASDAQ:AMGN) is in the Health Care sector and Biotechnology industry. Amgens Q2 earnings are confirmed for Thursday, August 3, 2023. Amgen and TScan Therapeutics announce collaboration to identify novel targets in Crohns Disease. Amgen (NASDAQ:AMGN) stock price for Amgen is $ 232.57 last updated July 18, 2023 at 8:00 PM UTC. Q2 earnings are confirmed for Thursday, August 3, 20 23. Amgen pays a quarterly cash dividend of $ 2.13 per share. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease Globe Newswire - May 9, 2023, 9:00am. Amgen Stock (NASDAQ:AMGN), Quotes and News Summary Amgen stock price, news, charts, charts and stock research, profile. Amgens final deadline is May 12. Amgen (NASDAQ:AMGN) stock price, news, charts, stock research, profile. Amgen is in the Health Care sector and Biotechnology industry. Amgens Q2 earnings are confirmed for Thursday, August 3, 2023. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease. Barclays Sticks to its Sell Rating for Amgen (AMGN) Amgen (NASDAQ:AMGN) reporting earnings are confirmed for Thursday, August 3, 2023. Amgen is in the Health Care sector and Biotechnology industry. There is no upcoming split for Amgen. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease. Amgen (NASDAQ:AMGN) stock price is $ 232.57 last updated July 18, 2023 at 8:00 PM UTC. Amgen is in the Health Care sector and Biotechnology. Amgen (AMGN) stock price is $ 232.57 last updated at 8:00 UTC. Amgen is reporting earnings for Thursday, August 3, 2023. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease. Amgen (NASDAQ:AMGN) is in the Health Care sector and Biotechnology industry. There is no upcoming split for Amgen. Amgen pays a quarterly cash dividend of $ 2.13 per share. The Amgen Safety Net Foundation helps qualifying patients access Amgen Medicines at no cost. For information regarding Amgens privacy practices, please view the Privacy Statement. By clicking the “I disagree” button below, the patients activation and enrollment into Amgen SupportPlus will be discontinued. By providing my phone number and selecting ‘I agree,” I consent to Amgen calling and texting me at the phone number(s) I have provided with promotional communications relating to products and services. Amgen SupportPlus patient may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle of the Amgen supportPlus product. Amgen will pay the remaining eligible out- of-pocket costs on behalf of the patient until Amgen payments have reached either the Maximum Program Benefit or Patient Total Program Benefit. Amgen, Inc.s (NASDAQ: AMGN) price prediction uncovers the downtrend of the AMGN stock price. Amgen SupportPlus Co-Pay Card benefits to reduce a patients out-of-pocket medication costs. Telos Capital Management Inc. Increases Stake in Amgen Inc., Demonstrating Confidence in the Medical Research Companys Future. With its return on equity standing at an astonishing 248.47% and a net margin of 30.23%, it is evident that Amgen possesses strong financial viability.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, price, AMGN, earnings, Therapeutics, NASDAQAMGN, and the most common words in the summary are: amgen, stock, amgn, inc, patient, job, program, . One of the sentences in the summary was: Amgen (AMGN) closed the most recent trading day at $227.66, moving +0.88% from the previous trading session. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #amgn #inc #patient #job #program.